Physician profile
Robert D Boyd
NPI 1548474257
$8,835.45
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,315 · 2020: $2,370 · 2021: $1,716 · 2022: $1,105 · 2023: $1,040 · 2024: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,216.49 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,697.67 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $813.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $789.40 | 2019-2024 | Xifaxan, Trulance, Cycloset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.22 | 2019-2023 | Jardiance, Spiriva Respimat |
| Glaxosmithkline, LLC. | $448.11 | 2019-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $424.94 | 2019-2022 | |
| Pfizer INC. | $293.00 | 2019-2022 | |
| Allergan, INC. | $292.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $253.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $220.84 | 2019-2021 | |
| Exact Sciences Corporation | $152.25 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $116.47 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $102.27 | 2019 | |
| Eisai INC. | $72.23 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $67.82 | 2022-2023 | Otezla, Repatha |
| Abbott Laboratories | $65.84 | 2021-2022 | |
| Abbvie INC. | $40.55 | 2021-2022 | |
| Esperion Therapeutics, INC. | $36.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.20 | 2019-2022 | |
| Horizon Therapeutics Plc | $25.97 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.79 | 2020 | |
| Mylan Specialty L.P. | $13.91 | 2019 | |
| Astellas Pharma US INC | $13.64 | 2019 | |
| Medicure Pharma INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.